Fulvestrant

Catalog No.S1191 Synonyms: ICI-182780, ZD 9238

Fulvestrant Chemical Structure

Molecular Weight(MW): 606.77

Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 71 Publications

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.
Targets
ER [1]
(Cell-free assay)
0.94 nM
In vitro

Fulvestrant is an effective inhibitor of the growth of ER-positive MCF-7 (with IC50 of 0.29 nM) but with no effect on the growth of ER-negative BT-20 human breast cancer cells. Fulvestrant causes accumulation of cells in G0/G1 and also reduces the proportion of cells capable of continued DNA synthesis. [1] Fulvestrant competitively inhibits binding of oestradiol to the estrogen receptor. Fulvestrant blocks nuclear localization of the ER through impairing receptor dimerisation, and energy-dependent nucleo-cytoplasmic shuttling. Because of the instability of fulvestrant-ER complex, the binding of Fulvestrant with ER finally results in accelerated degradation of the ER protein. [2] Fulvestrant (10 nM) not only decreases IGF-IR mRNA levels but also decreases the half-life. [3] Treatment with 100 μM Fulvestrant leads to a time dependent increase of TNFR1 and TRADD steady-state mRNA levels in MCF-7 cells. [4] Fulvestrant is capable of down-regulating androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Fulvestrant also significantly attenuates R1881-stimulated growth by 70%. [5] Fulvestrant is able to modulate mitosis and cell death in immature cerebellar neurons via rapid activation of MAPK. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnGTmUyNjNvMUCwNEBvVQ>? M17PZlQ5KGh? MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NInBZlgzPDl5OUK5OC=>
MCF-7/LTED NULrd243T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTqNU4{NTFyMECgcm0> MYO0PEBp NWTOVZN6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVKyOFk4QTJ7NB?=
HCC1428 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrNNU4{NTFyMECgcm0> MYG0PEBp NFW2[ZBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1;ZNVI1QTd7Mkm0
HCC1428/LTED MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXqOZQyNjNvMUCwNEBvVQ>? MYG0PEBp NYnSXGp2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnzhNlQ6Pzl{OUS=
LCC1 MX\GeY5kfGmxbjDBd5NigQ>? M1XEblExOCCwTR?= MWG0PE0yPDRiaB?= NVnkWo1z[WO2aY\heIV{KFWSUjDzbYdv[Wyrbne= MnnuNlQ5PTh{N{e=
LCC9 M4i4WmZ2dmO2aX;uJGF{e2G7 MXOxNFAhdk1? NYq1e|Y6PDhvMUS0JIg> MYThZ5RqfmG2ZYOgWXBTKHOrZ37hcIlv\w>? MXyyOFg2QDJ5Nx?=
MCF-7  NXLUdWVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF2yOlcyODBibl2= NHXuXGI2KGR? Mnr3bY5pcWKrdIOgZ4VtdCCpcn;3eIghfG9iMUFvwKU> NEnodmwzPDhzOUW1NC=>
mesangial  NWKzRW45TnWwY4Tpc44hSXO|YYm= M4TTSVAvOS1zMECgcm0> NIPaNFU1QCCq NHu1N|d{fXCycnXzd4V{KFSJRj5OtlEucW6mdXPl[EB1gXCnIFnWJINwdGyjZ3Xu MWqyOFc6OzZ|OR?=
Mesangial MVnGeY5kfGmxbjDBd5NigQ>? MW[wMlEuOTByIH7N NFexV3QxNjViaB?= MmnYbY5pcWKrdIOgWGdHNc7{MT3pcoR2[2WmIGPtZYQzKHCqb4PwbI9zgWyjdHnvckB3cWFiR2DFVi=> NWfNNHNROjR5OUO2N|k>
ER+ MCF-7/2a NYXIfpFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGraRVNKSzVyPUCuNFA1KM7:TR?= MUixOVMzPDh6NB?=
ER+ MCF-7 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\JRnVOOjByIHi= NFq0O|hKSzVyPUCuNlEhdk1? M3fIZVE2OzJ2OEi0
MCF-7  NIr3PYpHfW6ldHnvckBCe3OjeR?= NEjwZoIyOMLibl5CpC=> NWrTRnJHPzJiaB?= NGnXPW1z\X[ncoPld{B1cGViZYP0do9o\W5iZX\m[YN1MEmFNUCgNU46KMPZIEGw5qiTQSCPKR?= M3WxVFI1QTB6NkWy
MCF-7  NYPCeIoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jH[2lEPTEEoH;mJIFxeHKxeHntZZRmdHliMjDuUS=> M1jqWFI{PDR6M{S2
H1975  NI\IXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVizxsDPxE1? NI\aZ|kyKG1? MUHpcoNz\WG|ZYOgeIhmKGenZnn0bY5q[iC|ZX7zbZRqfmm2eTDv[kBJOTl5NTDj[Yxte8Li M{jLVlI1OjZ6OEGw
H1975 MU\GeY5kfGmxbjDBd5NigQ>? Mm[zN:Kh|ryP MnrLNUBu MmrreZBz\We3bHH0[ZMhfGinIHzleoVtKG:oIFzleE04[w>? NVrXdJFvOjR{Nki4NVA>
MCF-7  MkjmSpVv[3Srb36gRZN{[Xl? M2PkXFExOOLCiX7NxsA> NV3GZ5pTPzJiaB?= MUHy[ZZmenOnczD0bIUheHKxdHXjeIl3\SCnZn\lZ5Qhd2ZiRUNCpIlvKGOnbHygbY53[XOrb36= NIe4UXEzOzl|Nke3Ny=>
MCF-7  NYLmXoY1TnWwY4Tpc44hSXO|YYm= NWXWclBrOTBy4pEJcm3DqA>? MYqyOE81QCCq NI\VWVJn[WOrbHn0ZZRmeyCrbo\hd4lwdiC2aILveYdpKE2PUIOnJI1w\HWuYYTpc44> NEfmXFMzOzl|Nke3Ny=>
BT474-tet-shMED1 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HJNVAvOS13IN88US=> M{jUPVch\A>? NVzGdHpocW6lcnXhd4V{KCuGb4igbY5lfWOnZDDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYnxU5NNOjN7M{[yN|Q>
ZR75-1-tet-shMED1  NFfM[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[2OVAvOS13IN88US=> Mnu4O{Bl NIjQWJRqdmO{ZXHz[ZMhM0SxeDDpcoR2[2WmIHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MVKyN|k{PjJ|NB?=
MCF-7-tet-shMED1 NEG1SVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfnbHkxNjFvNTFOwG0> NVPkPWF2PyCm MnnHbY5kemWjc3XzJEtFd3hiaX7keYNm\CClZXzsJIRm[XSqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MlywNlM6OzZ{M{S=
HepG2  Mmi2SpVv[3Srb36gRZN{[Xl? NGXMPGMxNjBzLUGwJO69VQ>? M2HGelE5KGkEoB?= MlqwZYN1cX[jdHXzJJRp\SCHUlWtcYVlcWG2ZXSgeJJidnOlcnnweIlwdiCxZjDBSlJGWg>? NGP3RlczOzd|M{G4PC=>
MCF-7L  NGjVVHpHfW6ldHnvckBCe3OjeR?= MWGxNFAhdk4EoB?= MVqxNEBucW5xMkSgbE81QCCq MlmydoV{fWy2czDpckBGT0[ULDDISXIzKGGwZDDISXI{KHCqb4PwbI9zgWyjdHnvckBifCCycn;sc45o\WRiZYjwc5N2emV? Ml:4NlM3QDZ2MU[=
MCF-7L  NGfoNG5HfW6ldHnvckBCe3OjeR?= MnXvNVAxKG6PwrC= MVK0PEBp MV7pcoR2[2W|IIXwdoVofWyjdHnvckBw\iCvUl7BJI9nKEWJRmKgcIlo[W6mIFjCMWVITg>? MXeyN|Y5PjRzNh?=
MCF-7L MXvGeY5kfGmxbjDBd5NigQ>? NUnMc4YxOTByIH7NxsA> NILac5M1QCCq M4DiPYlv\HWlZYOgSWdHWiCoYX3pcJkhdWWvYnXyJIFkfGm4YYTpc44hemWzdXny[YQhTVJ? MVqyN|Y5PjRzNh?=
C4-12  M2PidWZ2dmO2aX;uJGF{e2G7 NFi5do0yODBibl5CpC=> M1LsPVQ5KGh? MWjpcoR2[2W|IFXHSnIh\mGvaXz5JI1mdWKncjDhZ5RqfmG2aX;uJJJmeXWrcnXkJGVT NXrmUZJJOjN4OE[0NVY>
MCF-7L MmHQSpVv[3Srb36gRZN{[Xl? NXTle48zOTByIH7NxsA> MkG5NlQhcA>? MnHjbY5lfWOnczDFS2ZTKHCqb4PwbI9zgWyjdHnvckBz\XG3aYLl[EBJSi2HR1[g[pVv[3Srb36= M3G1cVI{Pjh4NEG2
MMQ  NUTMfJRiTnWwY4Tpc44hSXO|YYm= MXuwMVYzPSCwTR?= NF7jcoc4OiCq NHnXSmxld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDld5Rzd2enbjDy[YNmeHSxcj5OtUApTVMQsTm= MljPNlM2OjN|NUe=
H1975  MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzDfFAxNjNzMkWtNVAh|ryP NHXyclM3KGR? NVe3UpFvcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1jhXlI{Ozl7OUW3
H1975  NETxVHZCeG:ydH;zbZMhSXO|YYm= MYOyNFAhdk1? MVW3NkBp NUfNbJFi\W6qYX7j[ZMh\XKub4TpcoljKGmwZIXj[YQh[XCxcITvd4l{ NWrYdHM1OjN|OUm5OVc>
MCF-7  NF32O|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfLNVAwOTByL{GwNFAhdk1? MoGyNk81NzZiZB?= MUHEUXNQ MoT2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= MlS1NlM{OTN3ME[=
MCF-7  NHTjZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nwSVExOCCwTR?= Mni1OEBl MkDmSG1UVw>? NXPxRpVScW6mdXPld{BiKGirZ3jldkBxem:yb4L0bY9vKG:oIHPlcIx{KGmwIITo[UBIOSCyaHHz[eKh NYTqVYZ1OjN|MUO1NFY>
MLO-Y4  MX7GeY5kfGmxbjDBd5NigQ>? MmL2NeKh|ryP MmLwNUBp MofqbY5pcWKrdIOgSVIucW6mdXPl[EBEgDR|IHX4dJJme3Orb36= NVzHeIQ6OjN{NEewOVc>
MCF-7 M4nnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLUR3UyODBibl2= NHzac4w1QCCq NVvoU4x[[WK{b3fheIV{KHSqZTDwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCvb3TldoF1\SCwaYTyc5NifGm4ZTDzeJJme3N? MoDjNlMzOTZ5NES=
TG1-1  MYDGeY5kfGmxbjDBd5NigQ>? M3vse|HDqM7:TR?= NEXNe4UzPCCq M3;mToFjem:pYYTld{BGOsLiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhUEmILUJOtS=> MUmyN|A5QDZyNx?=
TG1-1  NE\yc4lHfW6ldHnvckBCe3OjeR?= MnzxNeKh|ryP MV:yOEBp NYHtdphO[WK{b3fheIV{KEV{wrDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCSSUPL NVz0d4lLOjNyOEi2NFc>
MCF7 NGiyXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX5NVAxKG6P MnrkOFghcA>? M1LXU4xm[WS|IITvJIEhe2mvaXzhdkBtd3O|IHnuJJN2en[rdnHsJIF{KHerdHig[I95d3K3YnnjbY4h[WyxbnW= MYKyN|A4PzJ2OR?=
MCF7 M1ntW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXHSXBYOTByIH7N M4HZUlQ5KGh? NVfkSIFq\W6qYX7j[ZMhdnW2bHnuMY1m\GmjdHXkJINmdGxiZHXheIg> MnXVNlMxPzd{NEm=
MCF-7  MYnGeY5kfGmxbjDBd5NigQ>? M1HHdFYhcA>? M4XEWWROW09? NXXPOI1b[XS2ZX71ZZRmeyC2aHWg[ox2\GmxeH;ubYwuKG:{IH\lcohmgGGvaXStbY5lfWOnZDDpcoNz\WG|ZTDpckBucVJvMkGg[ZhxemW|c3nvci=> NHTXNmkzOzB3MkCzOi=>
MCF-7 NYP0bppGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKxNFAhdk1xMTFOwG0> MkPvOUBl NVTjO4t5cW6qaXLpeJMhfGinIIP0bY12dGG2aX;uJI9nKDF5zsKt[ZN1emGmaX;s NWe1T5E3OjJ7OEK3OlU>
MCF-7 M4nVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[xNFAhdk1? Ml\aOUBl NFK3SXZqdmirYnn0d{B1cGVic4TpcZVt[XSrb36gc4Yh\nW|YYLp[YxqdiCK MWWyNlk5Ojd4NR?=
1471.1 NH\6SIhHfW6ldHnvckBCe3OjeR?= NVfFbnBtOTByIH7N NYTtZmRNOSCq NIOxUGtGfE:KwrC= NIDtXZV1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> Mn3kNlI5PjlzME[=
MCF-7 MY\GeY5kfGmxbjDBd5NigQ>? M2Ox[VExOCCwTR?= NYnvNXo5OSCq MkSySZRQUMLi NIf6W|B1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> NUPTO2tjOjJ6NkmxNFY>
HeLa Mn\nSpVv[3Srb36gRZN{[Xl? NWDRUIdXOTByIH7N NEm5O2IyKGh? NGeyUHZGfE:KwrC= NUf0SG9RfGGtZYOgc44h[SCydX7jeIF1\SC|dHHpcolv\yCyYYT0[ZJv MYqyNlg3QTFyNh?=
COS-7  NWfwfWRwTnWwY4Tpc44hSXO|YYm= MmjhNVAxKG6P NUX0Z4FyOSCq M{\WdmV1V0kEoB?= Ml;XeIFs\XNib36gZUBxfW6ldHH0[UB{fGGrbnnu[{Bx[XS2ZYLu MX2yNlg3QTFyNh?=
BG1L-OHTLT  NHrLXWRHfW6ldHnvckBCe3OjeR?= NGX6PXcyOMLibl2= NGDjNHMzPMLiaNMg MYXpcohq[mm2czDFVu6yKGW6cILld5Nqd25? MnvONlI3PTJ3NUi=
BG1L-ICILT NE\K[pVHfW6ldHnvckBCe3OjeR?= M3PGVFExyqCwTR?= NX;aWHI{OjUEoHlCpC=> NWXxUGhycW6qaXLpeJMhTVMQsTDlfJBz\XO|aX;u M2q1Z|IzPjV{NUW4
PC-9 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ntfVAvODB|LUOwJO69VQ>? M2\RWFQ5KGh? MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmjwNlI2PjB4M{S=
H1650 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn61NE4xODNvM{Cg{txO Ml;IOFghcA>? NGjhfpZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVmyNlU3ODZ|NB?=
H1975 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTOR5JQOC5yMEOtN|Ah|ryP NGfa[4g1QCCq MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Ml\mNlI2PjB4M{S=
H1975 NWnUcGZ5TnWwY4Tpc44hSXO|YYm= NWLHXY9HO8LizszN Mkn6N{Bp NFHx[ZRi[nKxZ3H0[ZMhfGinIIDoc5NxcG9vRVfGVkBqdmS3Y4Tpc44h[nliZYP0do9o\W5? MljQNlI2PjB4M{S=
H1975 NV;KbmVbTnWwY4Tpc44hSXO|YYm= MmfkN:Kh|ryP MUS3JIQ> M4O0[olv\HWlZYOgSWdHWiCneIDy[ZN{cW:w NFLINZUzOjV4ME[zOC=>
HTR-8 MYfGeY5kfGmxbjDBd5NigQ>? NF;acnYyyqEQvF2= MWCxMVQ5KGh? NHjBWXFld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDJS2ZDWDdibWLORS=> NFXuVoEzOjN6M{GxNS=>
JEG-3 M3PYdGZ2dmO2aX;uJGF{e2G7 M2Xi[FHDqM7:TR?= MoPwNU01QCCq MnL0[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSVfGRnA4KG2UTlG= NXqxfYZYOjJ|OEOxNVE>
Huh7 MVrGeY5kfGmxbjDBd5NigQ>? MXG1NOKh|ryP MWe0PEBp NHXic|JqdmirYnn0d{Bo\W6rc4TlbY4udWWmaXH0[YQhWE:QMTD0doFve2GldHn2ZZRqd25? NYqzUHdZOjJ|MESyPVY>
201T MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXVb3U2KM7:TR?= MYS3NkBp NEXhNIxqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhidnHu[IV1[W6rYh?= M2TlPVIzOjV6NEe2
A549  NHfKdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3FNHE2KM7:TR?= NI\i[2Q4OiCq NWfZ[YtZcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= MU[yNlI2QDR5Nh?=
MCF-7 NWLXd2tZTnWwY4Tpc44hSXO|YYm= MX:xxsDPxE1? MlPRNlQhcMLi NW\4O|FY\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliND3PTE1VKMLi M3O1XlIzODR7M{G2
HCC-1428 NXTDOWxUTnWwY4Tpc44hSXO|YYm= MmDYNeKh|ryP NWLCeHhJOjRiaNMg NF36V3Nld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc44hcW6mdXPl[EBjgSB2LV;IMXQhyqB? M4nXflIzODR7M{G2
MDA-361 M2q0O2Z2dmO2aX;uJGF{e2G7 NWPr[JV{OcLizszN MXWyOEBpyqB? NF3ISIxld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc44hcW6mdXPl[EBjgSB2LV;IMXQhyqB? NVy1VVZ2OjJyNEmzNVY>
ZR75-1 MXfGeY5kfGmxbjDBd5NigQ>? NVfvfJd1OcLizszN NW[xWGRpOjRiaNMg NUjMdXh3\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliND3PTE1VKMLi NX7a[VljOjJyNEmzNVY>
MCF-7 NH;RXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYexxsDPxE1? M1fhZlUuOTBiZB?= MVPzeZBxemW|c3XzJGUzNWmwZIXj[YQh\3Kxd4ToJIlvcGmkaYTpc44> MlXkNlIxPDl|MU[=
HCC-1428 NHTtfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LQdlHDqM7:TR?= M1TQ[FUuOTBiZB?= MWnzeZBxemW|c3XzJGUzNWmwZIXj[YQh\3Kxd4ToJIlvcGmkaYTpc44> MmXKNlIxPDl|MU[=
MDA-361 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXyxxsDPxE1? MmHoOU0yOCCm NXPOW2pNe3WycILld5NmeyCHMj3pcoR2[2WmIHfyc5d1cCCrbnjpZol1cW:w NGn4XGozOjB2OUOxOi=>
ZR75-1 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki5NeKh|ryP MUO1MVExKGR? NHXtVFd{fXCycnXzd4V{KEV{LXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25? M13YUlIzODR7M{G2
MCF-7/AC-1 M1vFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvBVmxoOC1yLkKg{txO MXS2JIQ> M4rHeolvcGmkaYTzJINmdGxiZ4Lve5RpKG2xZHXzeIx6 MoKxNlIxPDJ5OUK=
MCF7 NFrRPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\YWVIyOCEEtV2= MnfDOFghcA>? MW\pcoR2[2W|IHPlcIwhcW6qaXLpeIlwdiC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkh\mmkcn;icIF{fHN? NYOyU4tCOjJyNEG4PFc>
MMQ NWTpeHh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorPNE03OjVibl2= M1TVV|czKGh? NHLlTXRxem:mdXPld{B{fGG2aYP0bYNidGy7IIPp[45q\mmlYX70JIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wwrC= MknYNlIxOTVzMEG=
MMQ Ml3YSpVv[3Srb36gRZN{[Xl? NVSwUGNCOC14MkWgcm0> NEDsV3k4OiCq Mo\udJJw\HWlZYOgZUB{fGG2aYP0bYNidGy7IIPp[45q\mmlYX70MEBld3OnLXTldIVv\GWwdDDy[YR2[3Srb36gbY4hWFKOIIPlZ5JmfGmxbh?= M2\PSlIzODF3MUCx
MCF7 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DqRVAuOSEQvF2= MXKyOE0yOjBiaB?= MorqbY5pcWKrdIOgeIhmKGe{b4f0bEBw\iCPQ1[3MXlDNTIEoB?= Mn[3NlE5PjN{NUi=
HepG2 NXPwW|JoSXCxcITvd4l{KEG|c3H5 MnntNE4yyqEQvF2= NHXvXVEzPCCq NXPQOIg{[WKxbHnzbIV{KHSqZTDld5Rzd2enbj3pcoR2[2WmIIXwMZJm\3WuYYTpc44hd2ZiYYDvRWkh[W6mIHHwc20> M1n2c|IyQDF4MkOz
MCF7–iFR3 Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXKyNE0yODBibl2= NIe2eJA6PiCq M3rxNoVvcGGwY3XzJGFRNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= Moi2NlE4QTJ6OEm=
MCF7S MoPCSpVv[3Srb36gRZN{[Xl? NFWwVlMyyqEQvF2= MXm0PEBp M2OyTYRwf26{ZXf1cIF1\XNib4\ldoFtdCCHUt8xJJBzd3SnaX6gcIV3\Wy| MnHUNlE2OzNzOUW=
MCF7 MV;GeY5kfGmxbjDBd5NigQ>? MmfRNeKh|ryP M2T3XlQ5KGh? NVrLO2Fb\G:5boLl[5Vt[XSnczDveoVz[WyuIFXS{tEheHKxdHXpckBt\X[nbIO= MlPGNlE2OzNzOUW=
MCF7S M2\1TGZ2dmO2aX;uJGF{e2G7 MUmxxsDPxE1? M3[yO|ch\A>? NYfjcI9U[XS2ZX71ZZRmeyC2dX3vdpNxcGW{ZTDmc5Ju[XSrb36gZY5lKHC{b3zp[oVz[XSrb36= MUWyNVU{OzF7NR?=
MCF7S MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXSNE42NzFizszN M1X0SFch\A>? NVfxOYFETE2VTx?= M1HlRoRm[3KnYYPld{Bk\WyuIHX4dIFve2mxbh?= MnXQNlE2OzNzOUW=
T47D  M2LmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXW0JI5O MUS0NEBp MmS2d5VxeHKnc4Pld{Bk\WyuIHfyc5d1cCCvb3TldoF1\Wy7 NY\0b5I6OjF2OECzPVE>
BT474  NYPOXW91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPCVYJxPCCwTR?= NXHhTI5[PDBiaB?= NXnpO3lMe3WycILld5NmeyClZXzsJIdzd3e2aDDtc4RmemG2ZXz5 NIi5e3AzOTR6MEO5NS=>
T47D  MU\GeY5kfGmxbjDBd5NigQ>? NGjicIwyOCCwTR?= MXe0NEBp NXmxOplF\G:5boLl[5Vt[XSnczDFVu6yKHC{b4TlbY4> NWrSO5o6OjF2OECzPVE>
BT474  MoroSpVv[3Srb36gRZN{[Xl? M4joU|ExKG6P NEHpPG41OCCq NIXKXnFld3ewcnXneYxifGW|IFXS{tEheHKxdHXpci=> MYqyNVQ5ODN7MR?=
MCF7 NIrUTWNHfW6ldHnvckBCe3OjeR?= M2GxWFExOCCwTR?= M2S4Xlch\A>? Ml3MdoVlfWOnczDFVu6yKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> NIPT[IYzOTN7NkC5OC=>
T47D  M3z4SWZ2dmO2aX;uJGF{e2G7 NV22PYJoOTByIH7N MWq3JIQ> M1LydJJm\HWlZYOgSXLPuSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> NH;NTG8zOTN7NkC5OC=>
BT474  MVHGeY5kfGmxbjDBd5NigQ>? NXPRbIQzOTByIH7N NYLRU3NuPyCm MYPy[YR2[2W|IFXS{tEh\XiycnXzd4lwdiC|aXfubYZq[2GwdHz5 M2XUOlIyOzl4MEm0
MDAMB361 MnPMSpVv[3Srb36gRZN{[Xl? MUmxNFAhdk1? MlrCO{Bl M3S2dpJm\HWlZYOgSXLPuSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> NW\MT3RyOjF|OU[wPVQ>
MCF7 NIDlPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTaeIUxNjBzLUGg{txO NVjJXXE5PyCm MorldoVlfWOnczDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MnjMNlE{QTZyOUS=
T47D  NGXDO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG0NE4xOS1zIN88US=> MWS3JIQ> NWW1UJdwemWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 NXjjPVNGOjF|OU[wPVQ>
BT474  NHTtO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHaUlJ7OC5yMT2xJO69VQ>? MWi3JIQ> MYny[YR2[2W|IHPlcIwh\3Kxd4ToJJNq\26rZnnjZY51dHl? MWSyNVM6PjB7NB?=
MDAMB361 M37NTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHmwfWMxNjBzLUGg{txO NH7TNXY4KGR? MXPy[YR2[2W|IHPlcIwh\3Kxd4ToJJNq\26rZnnjZY51dHl? NEL1fpozOTN7NkC5OC=>
MCF7 MWfGeY5kfGmxbjDBd5NigQ>? MoS5NVAxKG6P NXP2[5hFPyCm NVLQXnJscW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> MkW2NlE{QTZyOUS=
T47D  NHzUbm5HfW6ldHnvckBCe3OjeR?= NHLIVngyODBibl2= M{PKb|ch\A>? MUPpcoR2[2W|IH;mJGVz[kJ|IHHu[EBGemKENDDy[YNmeHSxcjDlfJBz\XO|aX;uJIFv\CC|aXfuZYxtcW6p MV:yNVM6PjB7NB?=
BT474  MVvGeY5kfGmxbjDBd5NigQ>? NIDSNY4yODBibl2= NX\R[GxyPyCm NHvmdI5qdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n M4H3[|IyOzl4MEm0
MDAMB361 M{naNmZ2dmO2aX;uJGF{e2G7 NYP0UYFyOTByIH7N M2K1WFch\A>? NVPMbZIxcW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> MnvXNlE{QTZyOUS=
MCF7 NXTxRXI3TnWwY4Tpc44hSXO|YYm= M{HkVlExKG6P M1vUTlk3KGh? Ml;l[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> MnrDNlE{Pzh|M{O=
MDA-MB-231 MkjGSpVv[3Srb36gRZN{[Xl? NH;nSIgyOCCwTR?= MlK2PVYhcA>? NUOwdIVk\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vyqB? MV2yNVM4QDN|Mx?=
SK-BR-3 MWHGeY5kfGmxbjDBd5NigQ>? NFWyTIQyOCCwTR?= NUPpXVk4QTZiaB?= M1vsR4Rwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvcuKh MofHNlE{Pzh|M{O=
MCF-7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWexNFAhdk1? MkfIO|IwQTZiaB?= M1P5XINifXOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MVWyNVI6QTh4Mh?=
MMQ NYWyO3FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMlAxQC14MkWgcm0> M{P0VFczKGh? NVHjN4dKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NG\rdlQzODdyMEe1OS=>
MMQ MWnGeY5kfGmxbjDBd5NigQ>? NHu1eXYxNjByOD22NlUhdk1? M3vrNVczKGh? M2i4[IlvcGmkaYTzJHBTVCC|ZXPy[ZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mm[4NlA4ODB5NUW=
MMQ MXrGeY5kfGmxbjDBd5NigQ>? NV\NUWl4OC5yND22NlUhdk1? NHnxdIQ4OiCq NHX0VnlqdmirYnn0d{BGWs7zIHX4dJJme3Orb36= NUPQ[4lDOjB5MEC3OVU>
MMQ NV3RcZdoTnWwY4Tpc44hSXO|YYm= NVLqc2x7OC5yND22NlUhdk1? NVzhNXZGPzJiaB?= M36zcpVxemWpdXzheIV{KFSJRt8yN{BidmRiVFfG{tJTUUliZYjwdoV{e2mxbh?= M2S1WlIxPzByN{W1

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MDM2 / ER; 

PubMed: 24747123     


MCF7 (A) and T47D (B) cells were cultured in the presence of different concentrations of fulvestrant (Fulv) for 66 h. ER and MDM2 were detected by Western blot and normalized to β-actin. The decrease in protein expression (shown relative to vehicle control treatment) after fulvestrant treatment was calculated for each drug concentration. *P < 0.05 compared to vehicle control treatment. 

p-ErbB3 Y1289 / ErbB3 / p-ErbB4 Y1056 / ErbB4 / p-AKT / AKT / p-ERK / ERK; 

PubMed: 21396094     


Western blots showing the effect of increasing concentrations of heregulin β1 (HRGβ1) (0.1 to 10 ng/ml for five minutes) on total and phosphorylated ErbB3, ErbB4, AKT and extracellular signal-regulated kinases 1 and 2 (ERK1/2) protein expression in MCF-7 and T47D cells, maintained for 7 days in the presence of either fulvestrant (100 nM) of vehicle control (ethanol). 

ErbB3; 

PubMed: 23999432     


Immunofluorescence of ErbB3 in cells cultured for 24 hours with or without fulvestrant. 

ERα; 

PubMed: 19815064     


Breast cancer cells were treated with different doses of ICI for 3 hours. The expression levels of ERα and actin were assayed by Western blot using anti-ERα and anti-actin antibodies.

24747123 21396094 23999432 19815064
Immunofluorescence
IGF-1R / Erα; 

PubMed: 19815064     


Confocal microscope study of fulvestrant-induced ERα and IGF-1R co-localization on the cell membrane in non-permeabilized condition. Cells were starved in 1% DCC medium for 24 hr and then treated with either vehicle (left) or ICI at 100 nM (right) for 15 min. Treated cells were fixed in 4% formaldehyde and stained with mouse monoclonal anti-IGF-1R antibody (a), rabbit polyclonal anti-ERα antibody (b), or nuclear staining with DAPI (c). The merged images are shown in d. Scale bar = 20 μm.

Snail / E-cadherin ; 

PubMed: 23936773     


E-cadherin and Snail protein localization in MCF-7 cells 48 h after treatment of cells with E2 and the tested agents. C: control (untreated cells); E2: cells treated with 17β-estradiol; Fulv: cells treated with E2 + 100 nM Fulv. The image is representative of three independent experiments using a magnification of 63X.

19815064 23936773
Growth inhibition assay
Cell viability; 

PubMed: 29787591     


MTT assay of MCF-7 cells treated with various concentration of fulvestrant. Statistically significant reduced the % viability in MCF-7 cells (One-way ANOVA; ****p < 0.0001).

29787591
In vivo Fulvestrant is devoid of uterotropic activity, and when co-administered with estradiol, it effectively blocks the uterotropic action of estradiol with ED50 of 0.06 mg/kg/day s.c. in immature female rats. A single s.c. injection of 5 mg of Fulvestrant suspension blocks completely the growth of MCF-7 xenografts. The growth of transplants of the BrlO human breast tumor is also suppressed effectively by 10 μM Fulvestrant. [1] Fulvestrant (10 mg/rat, s.c.) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. [7] Fulvestrant also displays anti-angiogenesis in the chick egg chorioallantoic membrane. [8]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: MCF-7 breast cancer cells
  • Concentrations: 2.9 nM
  • Incubation Time: 5 days
  • Method: MCF-7 cells are cultured in multiwell plates (24-well, seeding density 4 × 104) in minimal essential medium containing phenol red, insulin (10 μg/mL), and 5% charcoal-stripped fetal calf serum without additional estradiol. Fulvestrant and/or estradiol are added in fresh medium 2 days after seeding. Cultures are maintained for 5 days with one further medium change and growth is assessed by measurement of total cell protein at the beginning and end of treatment and compared with that of controls treated with ethanol (0.1%) alone.
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: The human breast cancer xenografts MCF-7 in nude mice
  • Formulation: 50 mg/mL in arachis oil
  • Dosages: 5 mg/mouse
  • Administration: s.c. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (164.8 mM)
Ethanol 100 mg/mL warmed (164.8 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
0.4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 606.77
Formula

C32H47F5O3S

CAS No. 129453-61-8
Storage powder
in solvent
Synonyms ICI-182780, ZD 9238

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04024436 Not yet recruiting Drug: TAS-120|Drug: Fulvestrant Metastatic Breast Cancer|FGFR2 Amplification Taiho Oncology Inc. August 30 2019 Phase 2
NCT03854903 Recruiting Drug: Palbociclib|Drug: Bosutinib|Drug: Fulvestrant Metastatic Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Hormone Receptor Positive Breast Cancer Georgetown University|Pfizer April 1 2019 Phase 1
NCT03584009 Recruiting Drug: Venetoclax|Drug: Fulvestrant Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer Hoffmann-La Roche September 6 2018 Phase 2
NCT03393845 Recruiting Drug: Pembrolizumab|Drug: Fulvestrant Breast Cancer Nancy Chan MD|Merck Sharp & Dohme Corp.|Big Ten Cancer Research Consortium January 29 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is there any information for the half-life of fulvestrant (Cat No.S1191)?

  • Answer:

    S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

Related Estrogen/progestogen Receptor Products

Tags: buy Fulvestrant | Fulvestrant ic50 | Fulvestrant price | Fulvestrant cost | Fulvestrant solubility dmso | Fulvestrant purchase | Fulvestrant manufacturer | Fulvestrant research buy | Fulvestrant order | Fulvestrant mouse | Fulvestrant chemical structure | Fulvestrant mw | Fulvestrant molecular weight | Fulvestrant datasheet | Fulvestrant supplier | Fulvestrant in vitro | Fulvestrant cell line | Fulvestrant concentration | Fulvestrant nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID